Protein Lounge has released Pathway Builder 2.0, a software tool for drawing signal transduction pathways. Pathway items such as membranes, protein/receptor shapes, and organelles are pre-made so users can select the items and arrange the pathway. A demo is available at http://www.proteinlounge.com/pathwaybuilder.asp.
Sage-N Research and the Institute for Systems Biology have partnered to release ISB's Trans-Proteomic Pipeline analysis platform as part of Sage-N Research's Sorcerer appliance. The Sorcerer appliance can be plugged into any network to deliver high- resolution, high-throughput data analysis through an easy-to-use web interface, the company said. With the integration of TPP, users can identify, characterize, and quantify proteins in complex mixtures using any vendor's LC-MS/MS data.
GeneGo has released MetaCore 3.0. The new version allows scientists to build combined signaling/metabolic networks from gene-expression, proteomics, metabolomics, high-content screening, siRNA, and other types of experimental data. MetaCore 3.0 also includes a parser for visualizing metabolomics data in the context of pathways, and adds an enterprise-wide data-management and user-access system.
Ariadne Genomics said that it plans to launch PathwayExpert, an enterprise-class software platform for pathway analysis, later this year. PathwayExpert will allow scientists to analyze microarray and proteomics data, create and share custom pathways for diseases, drug targets, and biomarkers, and mine the scientific literature. The new platform will add to Ariadne's PathwayAssist desktop product and PathwayStudio client-server platform. Ariadne said that several companies have agreed to beta-test the new platform. Further details on the beta-test program are available at http://www.ariadnegenomics.com/products/pathwayexpert.
Movers & Shakers
Hybrigenics named Rémi Delansorne as the new chief executive officer of the company this week.
Delansorne has been vice-president for R&D since 2004. Prior to Hybrigenics, he headed global research on diabetes at Merck KGaA in 2002 and worked with Monaco's Theramex. He has a doctorate in veterinary medicine from the Alfort Veterinary School.
The company also named Daan J. Ellens as chairman of its Board of Directors.
Ellens has his own biotechnology consultancy firm, Elkerim, and was the chief executive officer of RheinBiotech prior to its IPO and 2002 merger with Bema Biotech. He has a PhD in molecular biology from the State University of Utrecht and an MBA from the University of Eindhoven.
The appointments follow the death earlier this year of Bart Kwist, president and CEO.
Beckman Coulter has named Arnold A. Pinkston as senior vice president, general counsel, and secretary, the company said this week.
The vice-president and counsel appointments are effective Nov. 15, 2005. The secretary appointment is effective Dec. 1, pending Board approval. Pinkston will succeed William H. May, who is retiring.
Most recently, Pinkston was deputy general counsel for Lilly USA, part of the Eli Lilly Corporation. He currently serves on the Board of Directors of St. Vincent Health and Southwest Autism Research Center.
Kenneth L. Horton has been appointed executive vice-president and general counsel for MDS, the company said yesterday. He will join MDS at the start of December.
Horton was vice-president and general counsel for the Life and Analytical Sciences business unit of PerkinElmer prior to this appointment. He practiced corporate law with Boston's Ropes and Gray and a strategy consultant in the U.S. and Europe.
He has a J.D. from Harvard Law School and an A.B. from Dartmouth College.
Sigma-Aldrich's board of directors elected Avi Nash as a director, the company said this week.
Nash currently heads a management consulting firm, Avi Nash LLC, launched in 2003. Prior to this, he was a partner at Goldman Sachs. He has worked at Booz, Allen & Hamilton and UOP.
Outgoing chief executive officer David Harvey made the announcement.
The board also appointed Jai Nagarkatti, president and chief operating officer of the company since 2004, as president and chief executive officer to replace Harvey, who will remain chairman of the board.
Also elected to the board, Nagarkatti's appointment takes effect on Jan. 1, 2006.
Nagarkatti has been with Sigma-Aldrich for 29 years in R&D, production, operations and sales and marketing. He has a Master's degree in chemistry from Osmania University in Hyderabad, India, and a Ph.D. in organic chemistry from Texas A&M University.
Janet Woodcock, Deputy Commissioner of Operations and Chief Operating Officer at the U.S. Food and Drug Administration accepted the first Leadership in Personalized Medicine Award from the Personalized Medicine Coalition on Nov. 3 during a reception at the Harvard-Partners Center for Genetics and Genomics conference in Boston, MA.
"Through her determined initiative to introduce pharmacogenomics into the drug approval process, Dr. Woodcock has linked innovation to regulation in an effort to bring safer and more effective drugs to the American public," said PMC's executive director Edward Abrahams in a statement.
Michael Milburn has joined Metabolon as its chief scientific officer, the company said this week.
Prior to Metabolon, Milburn was senior vice-president of research and corporate development at Sirtris Pharmaceuticals. He was also senior vice-president of research at Plexxikon and held positions at Structural Genomix and GlaxoSmithKline.
He received his PhD in structural chemistry at the University of California, Berkeley, and was a research fellow at Harvard Medical School